Changes of plasma fibronectin in patients treated with cryofiltration for an extended period.
The purpose of this study was to evaluate correlations between extra domain A fibronectin (EDA[+]FN) in plasma and the clinical course in cryofiltration for an extended period. Two patients with systemic lupus erythematosus (SLE), 1 with aortitis syndrome, 1 with ankylosis spondylitis, 1 with polymyositis, 1 with rheumatoid arthritis, and 1 with chronic rejection of a kidney graft, were regularly treated with cryofiltration for more than 3 years. The average level of EDA(+)FN in each year did not show significant change in clinically stable patients with aortitis syndrome, polymyositis, and SLE. In the patient with ankylosis spondylitis, the average level of EDA(+)FN in each year elevated, so cryofiltration was performed frequently. On the other hand, cryofiltration could not attenuate the progression in the juvenile rheumatoid arthritis patient. In the patient with chronic rejection of a kidney graft, kidney function without hemodialysis could be prolonged for 33 months by cryofiltration. The average level of EDA(+)FN elevated as the graft function got worse. Changes of average level of EDA(+)FN in plasma corresponded with changes in the clinical courses of patients with autoimmune disease and chronic rejection of a kidney graft. The EDA(+)FN level might give prognostic information and determine the interval of cryofiltration.
Yonekawa
M
M
Department of Surgery, Sapporo Hokuyu Hospital, Japan.
Kawamura
A
A
Kukita
K
K
Meguro
J
J
Tanaka
M
M
Tamaki
T
T
D000328:Adult; D000704:Analysis of Variance; D001025:Aortitis / Q000097:blood / Q000628:therapy; D001171:Arthritis, Juvenile / Q000097:blood / Q000628:therapy; D001327:Autoimmune Diseases / Q000097:blood* / Q000175:diagnosis / Q000628:therapy*; D002648:Child; D005260:Female; D005353:Fibronectins / Q000097:blood*; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000628:therapy; D017583:Hemodiafiltration; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis / Q000379:methods*; D017285:Polymyositis / Q000097:blood / Q000628:therapy; D013167:Spondylitis, Ankylosing / Q000097:blood / Q000628:therapy; D016896:Treatment Outcome
D005353:Fibronectins